The only validated test to help inform your decision to extend or end endocrine therapy beyond year 5

Validated by studies of more than 1,500 patients in 3 prospective randomized clinical trial cohorts

Clinically actionable information
that can impact her treatment plan*

Biology Drives the Breast Cancer Index Result

Prospective study of 96 ER+ patients led by Yale University3

  • 26% of physician treatment recommendations related to extended endocrine therapy changed after Breast Cancer Index result
  • Breast Cancer Index resulted in net decrease in recommendations for extended endocrine therapy by 20% (from 74% to 54%)

Twice as many patients reported feeling strongly comfortable with their decision

~1/2 of Patients Reported:

  • A change in their treatment preference
  • Experiencing less anxiety (p=0.031), 13% had no change in anxiety

~2/3 of Patients Reported:

  • Decreased decisional conflict (p<0.001)
  • Knowing the results would make them more likely to be compliant with extended therapy

A LOW score on both components of BCI*

May support the decision to stop endocrine therapy

A HIGH score on both components of BCI*

May support decision to extend endocrine therapy and encourage tight adherence

Breast Cancer Index may help define your treatment strategy for each patient

See how BCI benefits patients throughout the treatment journey

BCI patient Scenarios

Tour the Test Report

Click on the test report numbers to learn more

BCI: clinically actionable information

…BCI might be useful in the setting of late disease recurrence, because it might provide a much needed means of identifying patients who could be spared extended adjuvant endocrine therapy and its well characterised adverse side-effects.

– Sgroi et al, TransATAC study, Lancet Oncol, 20132

References
  1. Data on file, Biotheranostics, Inc.
  2. Sgroi DC, et al. Lancet Oncol. 2013;14:1067 – 76.
  3. Sanft T, et al. Breast Cancer Res Treat. 2015;154(3):533-41.
Breast Cancer Index Intended Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.